Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.

Recipharm has joined forces with ProductLife Group (PLG) to support (bio)pharmaceutical firms in expediting market approval ...

We learn how CDMO Indena developed a bespoke synthetic API that had never been attempted before on such a scale, involving 30 ...

Just a day after dropping a $625m cancer asset, GSK has inked a deal worth a potential $2bn to acquire Boston Pharmaceuticals ...

Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline ...

Eligo Bioscience has secured a $5m grant from the French Government to expedite the development of its topical gene delivery ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Japan’s MHLW has approved Sarepta Therapeutics’ gene therapy Elevidys for treating Duchenne muscular dystrophy (DMD) ...

Orphan drug developers face significant difficulties when navigating market access frameworks in Europe. Could greater use of ...

Mobile healthcare, web-based tech, and wearables are all contributing to a clinical trials landscape that puts the patient ...

AI and machine learning can transform fragmented and unstructured healthcare data. But how do you refine it into useful, ...

The FDA has cleared the IND for Ensoma's EN-374, targeting X-linked chronic granulomatous disease (X-CGD), a rare genetic ...